• US: +1-408-610-2300
  • Toll Free: +1-866-831-4085
  • Login / Register
Prostate Cancer Diagnostic Market Size & Share, 2018 | Industry Report

Prostate Cancer Diagnostics Industry 2018 Market Research Report

Report ID: MN17613300  |  Published: April 2017  |  No of Pages: 136
Format: Electronic (PDF)  |  Industry: Therapeutic Area  |  Publisher: QY Research

Global Prostate Cancer Diagnostics Market is classified on the basis of product type, age, cancer stage, and geography. Male reproductive system consists of an exocrine gland which is situated below the bladder and front of the rectum is known as “prostate”. The basic function of prostate gland is to secrete fluid that nurtures and guards the sperms. The prostate squeezes this fluid into the urethra, and it’s pushed with sperm as semen during the course of ejaculation.

The most common cancer in men is Prostate Cancer, which is characterized by the abnormal development of cells in the prostate. There is an uncontrolled duplication of these abnormal cells and at times may extent in the surrounding parts of the prostate gland. It is usually a slow developing diseases. One of the distinguishing feature of prostate cancer is that it is an age dependent disease. This simply means that as the age increases there are possibilities of developing this type of cancer. Some of the factors that increase the risk of prostate cancer include family history, age, chemical exposures, smoking, inflammation of prostate, sexually transmitted infections, etc.

The factors that propel the growth of the Prostate Cancer Diagnostics Market include variation in lifestyle, growing awareness among people, and technological innovations. On the other hand, there are also factors that may hamper the growth of the market such as high expense of treatment. In addition, adverse effects of surgery such as urinary incontinence & impotence and surgical risks like stroke, heart attack, blood clots etc.

Prostate Cancer Diagnostics Market is classified on the basis of product typeastumour biomarker tests, imaging, biopsy and other. Biomarker is a substance that is obtained in the urine, body tissues or blood of cancerous patient. It is formed by the tumour or in response to cancer by the body. Some of the examples ofbiomarker tests for prostate cancer include the 4Kscore,Prostate Health Index (PHI), etc. Imaging basically uses the aid of sound waves, X-Rays, magnetic fields, etc. in order generate pictures of the inner body. Some of the most frequently used imaging test to determine prostate cancer include CT scan, bone scan, and MRI.

Biopsy is a diagnostic tool wherein samples of prostate are removed and seen below the microscope. Prostate biopsy is also called as a transrectal ultrasound (TRUS) or core needle biopsy. This process is usually carried out to detect if there is presence of a cancerous lump in the prostate gland and cause of high level of prostate-specific antigen (PSA) in blood. Prostate Cancer Diagnostics Industry is classified on the basis of ageas< 55, 55-75 and > 75. Prostate Cancer Diagnostics Market is classified on the basis ofcancer stage as stage I, stage II A, stage II B, stage III and stage IV. Prostate Cancer Diagnostics Market is classified on the basis of geography asNorth America, Latin America, Western Europe, Eastern Europe, Asia Pacific, Japan and Middle East and Africa.

The North American region consists of the U.S., and Canada. Latin America region consists of Mexico and Brazil. The Western European region consists of Germany, Italy, France, England and Spain. The Eastern European region consists of Poland and Russia. Asia Pacific region consists of China, India, ASEAN, Australia & New Zealand. The Middle East and Africa region consists of GCC, South Africa and North Africa.

In case of geographical region, U.S. is expected to account a major share of the Prostate Cancer Diagnostics Market. Some of the key players that fuel the growth of the Prostate Cancer Diagnostics Market include Genomic Health, Abbott, OPKO, Siemens Healthcare, DiaSorin, bioMeriux, Roche, MDx Health, Beckman Coulter, Myriad Genetics, Ambry Genetics, and others.

Market Segment:

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Prostate Cancer Diagnostics in these regions, from 2013 to 2025 (forecast), covering
• North America
• Europe
• China
• Japan
• Southeast Asia
• India

Global Prostate Cancer Diagnostics market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
• Genomic Health
• Abbott
• OPKO
• Siemens Healthcare
• DiaSorin
• bioMeriux
• Roche
• MDx Health
• Beckman Coulter
• Myriad Genetics
• Ambry Genetics

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
• Tumor Biomarker Tests
• Imaging
• Biopsy
• Other

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
• Under 55 Years Old
• 55-75 Years Old
• Above 75 Years Old

What questions do you have? Get quick response from our industry experts. Request More information
Key questions answered in the report include
key questions
We also offers customization on reports based on specific client requirement.
Request for Customization

Choose License Type

Research Assistance

Ryan Manuel
Ryan Manuel

Research Support Specialist, USA

  1. Phone: +1-408-610-2300
  2. Toll Free: +1-866-831-4085
  3. Email: [email protected]
  • World's largest premium report database
  • Transparent pre & post sale customer engagement model
  • Unparalleled flexibility in terms of rendering services
  • Safe & secure web experience
  • 24*5 Research support service
  • 100% Secure Payments
  • Our Promise
  • 100% Service Assurance
  • Market Monitoring
  • Service Flexibility
  • 24X5 Care available